Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without, or with Unknown,
Breast cancer susceptibility gene 1 or 2 status
Human epidermal growth factor receptor 2-negative breast cancer
Patient-reported outcomes
Poly (ADP-ribose) polymerase-inhibitor
Real-world evidence
Journal
Breast care (Basel, Switzerland)
ISSN: 1661-3791
Titre abrégé: Breast Care (Basel)
Pays: Switzerland
ID NLM: 101254060
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
06
10
2021
accepted:
05
03
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
24
1
2023
Statut:
ppublish
Résumé
This real-world study assessed the breast cancer susceptibility gene 1 or 2 mutation ( Oncologists abstracted data from medical charts of adult women who presented with HER2- ABC from February to May 2015 and from March to July 2017. Data were collected using a physician-reported form and a patient-reported form, which included questions on breast cancer history/treatment and questions from PRO instruments (EuroQol 5-Dimensions 3-Levels [EQ-5D-3L], Brief Pain Inventory [BPI], European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire Core 30 and its breast cancer module). In total, 742 oncologists provided data for 6,161 patients; 27.5% were tested for In patients with HER2- ABC in the real-world setting, more patients with
Identifiants
pubmed: 36684399
doi: 10.1159/000523970
pii: brc-0017-0460
pmc: PMC9851071
doi:
Types de publication
Journal Article
Langues
eng
Pagination
460-469Informations de copyright
2022 The Author(s). Published by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
Michael Patrick Lux received honoraria for lectures and performing in a consulting or advisory role for AstraZeneca, Eisai, Eli Lilly, Exact Sciences, Grünenthal, MSD, Novartis, Pfizer, PharmaMar, Pierre Fabre, Roche, and SamanTree; received reimbursed travel and accommodations expenses from Pfizer and Roche; has been an editorial board member of Medac; received fees for non-CME services from AstraZeneca, Eisai, Eli Lilly, Exact Sciences, Grünenthal, MSD, Novartis, Pfizer, Pierre Fabre, and Roche. Katie Lewis and Alex Rider are employees of Adelphi Real World, which received financial support from Pfizer for the development of this manuscript. Alexander Niyazov is a Pfizer employee and Pfizer stockholder.
Références
Future Oncol. 2014 Mar;10(4):499-502
pubmed: 24754577
Diabetes Metab Syndr Obes. 2016 Nov 01;9:371-380
pubmed: 27843332
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Eur J Cancer. 2021 Mar;146:30-47
pubmed: 33578357
JAMA. 2007 Mar 21;297(11):1233-40
pubmed: 17374817
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
Fam Cancer. 2012 Sep;11(3):351-4
pubmed: 22395474
Ann Surg Oncol. 2015 Mar;22(3):874-82
pubmed: 25527230
JAMA Netw Open. 2019 May 3;2(5):e194428
pubmed: 31125106
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2020 Jun 20;38(18):2080-2106
pubmed: 32243226
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Cancers (Basel). 2020 Jul 17;12(7):
pubmed: 32708835
Curr Med Res Opin. 2008 Nov;24(11):3063-72
pubmed: 18826746
J Clin Oncol. 2021 May 20;39(15):1619-1630
pubmed: 33780288
BMJ Open. 2016 Aug 16;6(8):e010352
pubmed: 27531722
PLoS One. 2017 Sep 28;12(9):e0185471
pubmed: 28957369
BMC Cancer. 2017 Jun 21;17(1):438
pubmed: 28637432
J Comp Eff Res. 2012 Sep;1(5):453-63
pubmed: 24236422
Cancer Manag Res. 2019 Mar 22;11:2321-2337
pubmed: 30962720
Front Pharmacol. 2021 Feb 26;11:632079
pubmed: 33716731
Mayo Clin Proc. 2010 Dec;85(12):1111-20
pubmed: 21123638
Clin Epidemiol. 2019 Jul 11;11:543-561
pubmed: 31372057
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
Front Pharmacol. 2018 Aug 21;9:909
pubmed: 30186165